Oyster Point Pharma Announces Publication in Ophthalmology of ONSET-2 Phase 3 Data on TYRVAYAᵀᴹ (varenicline solution) Nasal Spray
15 nov. 2021 07h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), ("Oyster Point Pharma" or "the Company") a commercial-stage biopharmaceutical company focused on the...
Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021
09 nov. 2021 07h01 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Third Quarter 2021 Financial Results and Recent Business Highlights
04 nov. 2021 16h05 HE
|
Oyster Point Pharma, Inc.
FDA Approval of TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021Field Force Onboarding Completed During Q3’21, U.S. Launch...
Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of The Signs and Symptoms of Dry Eye Disease
04 nov. 2021 08h00 HE
|
Oyster Point Pharma, Inc.
Oyster Point has launched a patient support program called TEAMTyrvaya™TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease PRINCETON,...
Oyster Point Pharma’s TYRVAYA™ (varenicline solution) Nasal Spray is Now Available at U.S. Regional Wholesalers for Distribution to Pharmacies for the Treatment of the Signs and Symptoms of Dry Eye Disease
03 nov. 2021 16h05 HE
|
Oyster Point Pharma, Inc.
TYRVAYA is the first and only nasal spray approved for the treatment of the signs and symptoms of dry eye disease TYRVAYA is designed to activate the trigeminal parasympathetic pathway resulting in...
Oyster Point Pharma to Present Data at the American Academy of Optometry Annual Meeting 2021
02 nov. 2021 16h45 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma to Report Third Quarter 2021 Financial Results on November 4, 2021
28 oct. 2021 07h00 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma, Inc., Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 sept. 2021 17h24 HE
|
Oyster Point Pharma, Inc.
PRINCETON, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Oyster Point Pharma Reports Second Quarter 2021 Financial Results and Recent Business Highlights
05 août 2021 16h02 HE
|
Oyster Point Pharma, Inc.
PDUFA Target Action Date for OC-01 (varenicline) Nasal Spray is October 17, 2021Initiated Hiring of U.S. Sales Representatives in July, with a Planned U.S. Launch of OC-01 (varenicline) Nasal Spray in...
Oyster Point Pharma Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize OC-01 and OC-02 in Greater China
05 août 2021 16h01 HE
|
Oyster Point Pharma, Inc.
Ji Xing Pharmaceuticals to develop and commercialize OC-01 (varenicline) and OC-02 (simpinicline) nasal sprays for patients with dry eye disease in Greater ChinaOyster Point Pharma will receive a...